NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer ...

Engaging in physical activity is a strategy that may enable patients to live longer after their cancer diagnosis and live a length of life that begins to approximate the national norms,” said Justin C ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 2 ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

Fabiano do Nascimento was born in Rio de Janeiro and is based in Los Angeles and Japan. The guitarist, composer, arranger and producer is known for his intricately woven, multi-string performances, ...

"Matterhorn is the first phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction ...

The following is a summary of “5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response,” published in the March 2025 issue of Journal of the American Academy ...

Medicare will cover chemotherapy for treating cancer. Because doctors administer fluorouracil intravenously (via the veins), coverage falls under Part A or B. Part A covers it during a hospital ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Leukopenia, weight loss and oral mucositis induced by 5-Fluorouracil in hamsters' model: A regenerative ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Use of ...